Q1 EPS Estimates for Revolution Medicines Lifted by Wedbush

Revolution Medicines, Inc. (NASDAQ:RVMD) – Research analysts at Wedbush boosted their Q1 2025 earnings estimates for shares of Revolution Medicines in a report released on Wednesday, February 26th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings of ($0.89) per share for the quarter, up from their prior estimate of ($0.90). Wedbush has a “Outperform” rating and a $67.00 price objective on the stock. The consensus estimate for Revolution Medicines’ current full-year earnings is ($3.49) per share. Wedbush also issued estimates for Revolution Medicines’ Q2 2025 earnings at ($0.91) EPS, Q3 2025 earnings at ($0.95) EPS, Q4 2025 earnings at ($0.97) EPS, FY2025 earnings at ($3.73) EPS, FY2026 earnings at ($3.96) EPS, FY2027 earnings at ($3.72) EPS, FY2028 earnings at ($2.08) EPS and FY2029 earnings at $2.90 EPS.

Revolution Medicines (NASDAQ:RVMD) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.11).

RVMD has been the topic of a number of other reports. Needham & Company LLC reduced their price objective on shares of Revolution Medicines from $60.00 to $59.00 and set a “buy” rating on the stock in a research report on Thursday, February 27th. HC Wainwright upped their target price on shares of Revolution Medicines from $72.00 to $73.00 and gave the stock a “buy” rating in a research report on Monday. Guggenheim upped their target price on shares of Revolution Medicines from $82.00 to $87.00 and gave the stock a “buy” rating in a research report on Tuesday, December 3rd. UBS Group upped their target price on shares of Revolution Medicines from $65.00 to $71.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Finally, Stifel Nicolaus reduced their target price on shares of Revolution Medicines from $80.00 to $78.00 and set a “buy” rating on the stock in a research report on Thursday, February 27th. Twelve investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Revolution Medicines currently has a consensus rating of “Buy” and a consensus price target of $66.31.

Revolution Medicines Trading Down 1.0 %

Shares of Revolution Medicines stock opened at $37.96 on Monday. The company’s fifty day simple moving average is $41.91 and its two-hundred day simple moving average is $46.15. The company has a market cap of $6.39 billion, a P/E ratio of -10.57 and a beta of 1.45. Revolution Medicines has a 12-month low of $29.15 and a 12-month high of $62.40.

Insider Activity at Revolution Medicines

In other Revolution Medicines news, Director Thilo Schroeder acquired 1,304,347 shares of the stock in a transaction that occurred on Thursday, December 5th. The shares were acquired at an average cost of $46.00 per share, with a total value of $59,999,962.00. Following the transaction, the director now owns 2,096,612 shares of the company’s stock, valued at $96,444,152. The trade was a 164.64 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Mark A. Goldsmith sold 11,714 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $45.40, for a total value of $531,815.60. Following the completion of the transaction, the insider now directly owns 325,056 shares in the company, valued at $14,757,542.40. This trade represents a 3.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 18,678 shares of company stock valued at $847,981. 8.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Revolution Medicines

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. IFP Advisors Inc bought a new position in Revolution Medicines in the 4th quarter valued at approximately $34,000. Quarry LP purchased a new stake in Revolution Medicines during the 3rd quarter valued at $82,000. Sterling Capital Management LLC raised its stake in Revolution Medicines by 588.7% during the 4th quarter. Sterling Capital Management LLC now owns 1,956 shares of the company’s stock valued at $86,000 after buying an additional 1,672 shares during the last quarter. Farther Finance Advisors LLC raised its stake in Revolution Medicines by 368.3% during the 4th quarter. Farther Finance Advisors LLC now owns 2,051 shares of the company’s stock valued at $90,000 after buying an additional 1,613 shares during the last quarter. Finally, Kapitalo Investimentos Ltda purchased a new stake in Revolution Medicines during the 4th quarter valued at $104,000. 94.34% of the stock is owned by institutional investors.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.